- Adalimumab is a monoclonal antibody, marketed under the brand name Humira. Adalimumab is marketed by the pharmaceutical company AbbVie.
- It is a Phage display-derived therapeutic antibodies, humanized by Phage display guided selection using a naïve scFv-phage library using Cambridge Antibody Technology (CAT)
- Antibody format: IgG1-κ
- It functions by blocking a tumor necrosis factor-alpha (TNF-α), a cytokine involved in systemic inflammation.
- It is available under the brand name Humira, as well as biosimilars (which are like generic versions of brand-name drugs). It is administered via subcutaneous injection (under the skin).
- It an be used to treat several inflammatory/autoimmune conditions
- Rheumatoid arthritis (Approved 2002)
- Psoriatic arthritis (Approved 2005)
- Ankylosing spondylitis (Approved 2006)
- Crohn’s disease (Approved 2007)
- Psoriasis, severe chronic plaque (Approved 2008)
- Juvenile Idiopathic Arthritis (Approved 2008)
- Ulcerative colitis (Approved 2012)
- Hidradenitis suppurativa (Approved 2015)
- Fingernail psoriasis (Approved 2017)
- Common side effects may include injection site reactions, increased risk of infections, headaches and nausea.
- Abbreviations:
- TNF-α (tumor necrosis factor-alpha)
Note: The information presented here is for informational purposes only and should not be considered a substitute for professional medical advice. Always consult a healthcare provider for personalized guidance and recommendations.
Disclaimer: While we strive to provide accurate and up-to-date information, we cannot guarantee 100% accuracy. Please consult additional sources for verification.
Was this post helpful?
Let us know if you liked the post. That’s the only way we can improve.